Alcolea D, Vilaplana E, Suárez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, Lladó A, Sánchez-Valle R, Molinuevo JL, García-Ribas G, Compta Y, Martí MJ, Piñol-Ripoll G, Amer-Ferrer G, Noguera A, García-Martín A, Fortea J, Lleó A. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 Jul 11;89(2):178-188. Epub 2017 Jun 7 PubMed.
AlzBiomarker Database
Meta-Analysis
- AD vs CTRL : Aβ42 (CSF)
- CBS vs AD : Aβ42 (CSF)
- CTRL vs AD : Aβ42 (CSF)
- FTD vs AD : Aβ42 (CSF)
- PSP vs AD : Aβ42 (CSF)
- AD vs CTRL : NFL (CSF)
- CBS vs AD : NFL (CSF)
- CTRL vs AD : NFL (CSF)
- FTD vs AD : NFL (CSF)
- PSP vs AD : NFL (CSF)
- AD vs CTRL : YKL-40 (CSF)
- CBS vs AD : YKL-40 (CSF)
- CTRL vs AD : YKL-40 (CSF)
- FTD vs AD : YKL-40 (CSF)
- PSP vs AD : YKL-40 (CSF)
- AD vs CTRL : sAPPβ (CSF)
- CBS vs AD : sAPPβ (CSF)
- CTRL vs AD : sAPPβ (CSF)
- FTD vs AD : sAPPβ (CSF)
- PSP vs AD : sAPPβ (CSF)
- AD vs CTRL : tau-p181 (CSF)
- CBS vs AD : tau-p181 (CSF)
- CTRL vs AD : tau-p181 (CSF)
- FTD vs AD : tau-p181 (CSF)
- PSP vs AD : tau-p181 (CSF)
- AD vs CTRL : tau-total (CSF)
- CBS vs AD : tau-total (CSF)
- CTRL vs AD : tau-total (CSF)
- FTD vs AD : tau-total (CSF)
- PSP vs AD : tau-total (CSF)
Curated Study Data
Biomarker (Source) |
Cohort (N) |
Measurement Mean ± SD |
Method; Assay Name; Manufacturer |
Diagnostic Criteria |
---|---|---|---|---|
Aβ42 (CSF) |
AD (72) |
346.3 ± 105.2 pg/mL § |
ELISA; ; Fujirebio |
McKhann et al., 2011 |
Aβ42 (CSF) |
CBS (20) |
480.1 ± 165.3 pg/mL § |
ELISA; ; Fujirebio |
|
Aβ42 (CSF) |
CTRL (56) |
780.4 ± 145.7 pg/mL § |
ELISA; ; Fujirebio |
|
Aβ42 (CSF) |
FTD- FTLD-TDP43 (15) |
594.2 ± 236.3 pg/mL § |
ELISA; ; Fujirebio |
|
Aβ42 (CSF) |
FTD- bvFTD (68) |
653 ± 270.7 pg/mL § |
ELISA; ; Fujirebio |
Rascovsky et al., 2011 |
Aβ42 (CSF) |
FTD- nfvPPA (23) |
637.7 ± 168.5 pg/mL § |
ELISA; ; Fujirebio |
Gorno-Tempini et al., 2011 |
Aβ42 (CSF) |
FTD- svPPA (19) |
764.5 ± 247.6 pg/mL § |
ELISA; ; Fujirebio |
Gorno-Tempini et al., 2011 |
Aβ42 (CSF) |
PSP (28) |
452.2 ± 198.6 pg/mL § |
ELISA; ; Fujirebio |
Litvan et al., 1996 |
NFL (CSF) |
AD (55) |
1051.8 ± 395.4 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
McKhann et al., 2011 |
NFL (CSF) |
CBS (19) |
2264.3 ± 1216.5 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
|
NFL (CSF) |
CTRL (56) |
447.6 ± 207.4 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
|
NFL (CSF) |
FTD- bvFTD (54) |
2174.4 ± 2394.9 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
Rascovsky et al., 2011 |
NFL (CSF) |
FTD- nfvPPA (10) |
2042.4 ± 1617.3 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
Gorno-Tempini et al., 2011 |
NFL (CSF) |
FTD- svPPA (11) |
2394.4 ± 1388.1 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
Gorno-Tempini et al., 2011 |
NFL (CSF) |
PSP (28) |
1469.8 ± 656.9 pg/mL § |
ELISA; NF-light; UmanDiagnostics AB |
Litvan et al., 1996 |
YKL-40 (CSF) |
AD (70) |
280.3 ± 47.6 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
McKhann et al., 2011 |
YKL-40 (CSF) |
CBS (21) |
280.6 ± 60.4 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
|
YKL-40 (CSF) |
CTRL (56) |
195.9 ± 43 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
|
YKL-40 (CSF) |
FTD- FTLD-TDP43 (14) |
266.2 ± 63.8 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
|
YKL-40 (CSF) |
FTD- bvFTD (63) |
253.6 ± 69.1 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
Rascovsky et al., 2011 |
YKL-40 (CSF) |
FTD- nfvPPA (23) |
287.5 ± 59 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
Gorno-Tempini et al., 2011 |
YKL-40 (CSF) |
FTD- svPPA (15) |
287.1 ± 49.9 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
Gorno-Tempini et al., 2011 |
YKL-40 (CSF) |
PSP (21) |
253.3 ± 61.3 ng/mL § |
ELISA; MicroVue; Quidel Corporation |
Litvan et al., 1996 |
sAPPβ (CSF) |
AD (72) |
1015.5 ± 346.7 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
McKhann et al., 2011 |
sAPPβ (CSF) |
CBS (21) |
556.4 ± 226.9 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
|
sAPPβ (CSF) |
CTRL (56) |
972.8 ± 383.8 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
|
sAPPβ (CSF) |
FTD- FTLD-TDP43 (15) |
562.1 ± 196.5 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
|
sAPPβ (CSF) |
FTD- bvFTD (68) |
546.6 ± 243.3 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
Rascovsky et al., 2011 |
sAPPβ (CSF) |
FTD- nfvPPA (23) |
639.6 ± 296.5 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
Gorno-Tempini et al., 2011 |
sAPPβ (CSF) |
FTD- svPPA (19) |
596.9 ± 233.8 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
Gorno-Tempini et al., 2011 |
sAPPβ (CSF) |
PSP (28) |
543.7 ± 246 ng/mL § |
ELISA; human sAPPβ-w, highly sensitive; IBL |
Litvan et al., 1996 |
tau-p181 (CSF) |
AD (72) |
106 ± 34.5 pg/mL § |
ELISA; ; Fujirebio |
McKhann et al., 2011 |
tau-p181 (CSF) |
CBS (21) |
43.4 ± 13.3 pg/mL § |
ELISA; ; Fujirebio |
|
tau-p181 (CSF) |
CTRL (56) |
39.2 ± 10.7 pg/mL § |
ELISA; ; Fujirebio |
|
tau-p181 (CSF) |
FTD- FTLD-TDP43 (15) |
37.3 ± 8.9 pg/mL § |
ELISA; ; Fujirebio |
|
tau-p181 (CSF) |
FTD- bvFTD (68) |
43.5 ± 20.8 pg/mL § |
ELISA; ; Fujirebio |
Rascovsky et al., 2011 |
tau-p181 (CSF) |
FTD- nfvPPA (23) |
60.8 ± 29.7 pg/mL § |
ELISA; ; Fujirebio |
Gorno-Tempini et al., 2011 |
tau-p181 (CSF) |
FTD- svPPA (19) |
47.8 ± 18.2 pg/mL § |
ELISA; ; Fujirebio |
Gorno-Tempini et al., 2011 |
tau-p181 (CSF) |
PSP (28) |
34.9 ± 23.9 pg/mL § |
ELISA; ; Fujirebio |
Litvan et al., 1996 |
tau-total (CSF) |
AD (72) |
844.9 ± 370.5 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
McKhann et al., 2011 |
tau-total (CSF) |
CBS (21) |
279.5 ± 108 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
|
tau-total (CSF) |
CTRL (56) |
194 ± 64.1 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
|
tau-total (CSF) |
FTD- FTLD-TDP43 (15) |
269 ± 100.2 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
|
tau-total (CSF) |
FTD- bvFTD (68) |
273.8 ± 151.5 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
Rascovsky et al., 2011 |
tau-total (CSF) |
FTD- nfvPPA (23) |
376.2 ± 222.9 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
Gorno-Tempini et al., 2011 |
tau-total (CSF) |
FTD- svPPA (19) |
315.4 ± 158.3 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
Gorno-Tempini et al., 2011 |
tau-total (CSF) |
PSP (28) |
214.9 ± 131.6 pg/mL § |
ELISA; Innotest hTAU-Ag; Fujirebio |
Litvan et al., 1996 |
§ Data supplied to Alzforum by author
Recommends
Please login to recommend the paper.
This paper appears in the following:
AlzBiomarker
- AD vs CTRL : Aβ42 (CSF)
- CBS vs AD : Aβ42 (CSF)
- CTRL vs AD : Aβ42 (CSF)
- FTD vs AD : Aβ42 (CSF)
- PSP vs AD : Aβ42 (CSF)
- AD vs CTRL : NFL (CSF)
- CBS vs AD : NFL (CSF)
- CTRL vs AD : NFL (CSF)
- FTD vs AD : NFL (CSF)
- PSP vs AD : NFL (CSF)
- AD vs CTRL : YKL-40 (CSF)
- CBS vs AD : YKL-40 (CSF)
- CTRL vs AD : YKL-40 (CSF)
- FTD vs AD : YKL-40 (CSF)
- PSP vs AD : YKL-40 (CSF)
- AD vs CTRL : sAPPβ (CSF)
- CBS vs AD : sAPPβ (CSF)
- CTRL vs AD : sAPPβ (CSF)
- FTD vs AD : sAPPβ (CSF)
- PSP vs AD : sAPPβ (CSF)
- AD vs CTRL : tau-p181 (CSF)
- CBS vs AD : tau-p181 (CSF)
- CTRL vs AD : tau-p181 (CSF)
- FTD vs AD : tau-p181 (CSF)
- PSP vs AD : tau-p181 (CSF)
- AD vs CTRL : tau-total (CSF)
- CBS vs AD : tau-total (CSF)
- CTRL vs AD : tau-total (CSF)
- FTD vs AD : tau-total (CSF)
- PSP vs AD : tau-total (CSF)
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.